What are leachables and migratables?

Leachables are substances that migrate into a drug product from its container or closure system during storage, while migratables refer more broadly to all substances that can be transferred from the packaging under real use or storage conditions. These substances may arise from inks, adhesives, rubber stoppers, or plasticizers and can compromise product quality, safety, and efficacy. Including their evaluation in stability programs is essential to ensure compatibility over the product’s shelf life.

Why this matters for pharmaceutical safety:

Without leachable and migratable testing:

• Undetected substances may pose toxicity risks
• Regulatory submissions may be rejected or delayed
• Unexpected impurities could exceed ICH Q3B limits
• Stability failures may be linked to packaging instead of formulation

Proactively assessing leachables protects patients and strengthens your product’s regulatory acceptance.

Regulatory and Technical Context:

ICH and WHO recommendations on container-closure compatibility:

ICH Q3B emphasizes the need to monitor degradation products, including those that may result from packaging interaction. WHO TRS 1010 and FDA guidance stress that the container-closure system should not affect product safety or efficacy throughout the shelf life. CTD Modules 3.2.P.2 and 3.2.P.7 must describe material compatibility, while Module 3.2.P.8.3 should summarize testing outcomes, including any leachable-related concerns.

Audit expectations and global regulatory standards:

Inspectors typically review:

• Leachables and extractables reports
• Toxicological risk assessments for detected species
• Justification for selecting specific packaging materials

Absence of these evaluations may result in data deficiencies, additional testing mandates, or shelf-life re-evaluation.

Best Practices and Implementation:

Begin with extractables testing and risk prioritization:

Start by:

• Conducting extractables studies under exaggerated conditions
• Identifying compounds using GC-MS, LC-MS, and ICP-MS
• Creating a leachables target list for routine monitoring

Prioritize risk based on dosage form (e.g., higher risk for injectables or inhalation products).

Perform leachables testing at real-time and accelerated intervals:

Include leachables testing:

• At initial (0M), intermediate (6M), and final (12M/24M) stability time points
• For all intended storage conditions (long-term, accelerated)
• On samples stored in final commercial packaging

Use validated analytical methods sensitive enough to detect trace levels of known or unknown leachables.

Document all findings and link to product safety profile:

Ensure:

• Toxicological thresholds (e.g., PDEs) are compared against observed levels
• Reports are reviewed and approved by QA and toxicology teams
• Results are archived and summarized in regulatory dossiers

Link findings to formulation and packaging development reports to demonstrate comprehensive risk control.

Integrating leachable and migratable testing into your stability study framework is vital for long-term product safety and global regulatory approval. It reflects a mature quality system and a science-driven approach to pharmaceutical risk management.

Why impurity trend monitoring is essential:

Impurity profiling involves evaluating known and unknown degradants across multiple stability time points. It reveals whether degradation is linear, accelerating, or plateauing—and helps determine if impurities remain below safety thresholds. Without such profiling, emerging risks may go unnoticed, resulting in ineffective shelf-life justification or post-market issues.

How stability trends support regulatory and quality objectives:

Impurity trends help identify critical points where degradation may spike, such as during accelerated storage or under certain climatic conditions. This data validates formulation robustness, identifies formulation-process interactions, and supports proactive CAPA (Corrective and Preventive Action) measures. Regulatory agencies expect impurity profiles as part of the justification for product expiry dating.

Regulatory and Technical Context:

ICH and global guidance on impurity tracking:

ICH Q1A(R2) and Q3B(R2) mandate impurity tracking over the full shelf-life period for drug substances and drug products. The goal is to ensure that any degradation-related impurities—whether process-related, reactive, or formed due to packaging interaction—stay within acceptable toxicological limits. WHO TRS 1010 and EMA/CHMP guidelines also stress comprehensive impurity monitoring as a key part of stability data submission in CTD Module 3.2.P.8.3.

Inspection and submission expectations:

Regulators expect complete impurity profiles at each stability time point under both long-term and accelerated conditions. Submissions that fail to trend data across batches or omit impurity characterizations can face delays or rejections. During audits, raw chromatograms and trend reports are reviewed to confirm integrity and consistency.

Best Practices and Implementation:

Design protocols with impurity tracking built in:

Ensure that every scheduled time point includes impurity testing using validated stability-indicating methods such as HPLC or UPLC. The method should resolve all known and unknown degradants with sensitivity appropriate for ICH Q3B thresholds. Include trending templates in your protocol to track all major and minor impurity levels by time, temperature, and storage condition.

Analyze impurity results batch-wise and look for patterns of increase, plateau, or non-linearity to adjust shelf-life estimates accordingly.

Evaluate degradation pathways and identify unknowns:

Where new peaks emerge, use LC-MS, NMR, or other advanced techniques to identify and quantify unknown degradants. Compare with forced degradation studies to correlate peak identities and assign likely pathways (e.g., oxidation, hydrolysis, photolysis). Evaluate whether observed degradants are consistent with stress data or indicate formulation-packaging interactions.

Document impurity growth kinetics and conduct risk assessments when thresholds approach specification limits.

Integrate impurity trends into regulatory documentation and decision-making:

Present impurity trend graphs and tables in CTD Module 3.2.P.8.3 for each stability condition. Justify the assigned shelf life based on time-point results and impurity thresholds. Reference how impurity trends are monitored in real time as part of your Product Quality Review (PQR) and Continuous Process Verification (CPV) strategies.

Use impurity trends to trigger pre-emptive stability revalidation, packaging updates, or specification tightening if adverse patterns emerge. This reinforces your proactive QA culture and builds regulatory trust.